Abstract: SA-PO0306
Intracellular Lipid Accumulation and Injury in Diabetic Kidney Disease and the Effect of Newly Synthesized Cyclodextrin
Session Information
- Diabetic Kidney Disease: Basic and Translational Science Advances - 2
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- 701 Diabetic Kidney Disease: Basic
Authors
- Ryu, Jaejin, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea (the Republic of)
- Kang, Dong Hoon, National Health Insurance Service Ilsan Hospital, Goyang-si, Gyeonggi-do, Korea (the Republic of)
- Nam, Boyoung, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea (the Republic of)
- Yoo, Tae-Hyun, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea (the Republic of)
Group or Team Name
- Institute of Kidney Disease Research.
Background
Lipid dysmetabolism is one of the key pathogenic mechanisms and a potential therapeutic target in diabetic kidney disease. Cyclodextrins have been used to modulate cholesterol metabolism due to their ability to bind to and solubilize cholesterol; however, their non-specific cholesterol depletion induces cytotoxicity, limiting their therapeutic use.
Methods
In this study, we evaluated the therapeutic potential of a newly synthesized cyclodextrin (NCD). In vivo experiments were conducted in db/db and db/m mice administered with vehicle or NCD at doses of 200, 500, or 2000 mg/kg. In vitro, mouse mesangial cells were treated with 50ug of fluorescent labeled cholesterol crystals followed by hydroxypropyl beta-cyclodextrin (HPβCD) or NCD.
Results
In vivo, db/db mice exhibited significant elevation of serum creatinine, proteinuria, and kidney cholesterol contents compared to db/m controls. Treatment with NCD demonstrated kidney protective effects, with dose-dependent reductions in serum creatinine and proteinuria, as well as markedly reduced kidney cholesterol contents. In vitro, NCD effectively promoted cholesterol efflux in mesangial cells. Compared to hydroxypropyl beta-cyclodextrin (HPβCD), NCD showed excellent cell viability and minimal toxicity.
Conclusion
Our findings suggest that NCD may serve as a promising therapeutic candidate in diabetic kidney disease.
Funding
- Government Support – Non-U.S.